Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Severe Hypertriglyceridemia (sHTG)”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05852431
What this trial is testing

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Who this might be right for
Severe Hypertriglyceridemia
89bio, Inc. 360
Not applicableAvailableNCT06796426
What this trial is testing

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Who this might be right for
Familial ChylomicronemiaHigh Risk Severe Hypertriglyceridemia (SHTG)
Arrowhead Pharmaceuticals
Large-scale testing (Phase 3)Active Not RecruitingNCT05681351
What this trial is testing

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Who this might be right for
Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc. 885
Testing effectiveness (Phase 2)Study completedNCT03452228
What this trial is testing

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Who this might be right for
Severe Hypertriglyceridemia (sHTG)
Regeneron Pharmaceuticals 52
Early research (Phase 1)Looking for participantsNCT07491172
What this trial is testing

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Who this might be right for
CardiovascularMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG 90